New clinical data from Phase 1 trial of ZW191 to be presented in an oral presentation on April 21Preclinical data highlight combination potential for ZW191, a folate receptor alpha (FR⍺)-targeting antibody-drug conjugate (ADC)New ADC candidates, including ZW437 and ZW418, demonstrate strong activity across RAS-mutated cancers based on a novel pan-RAS inhibitor ADC platform VANCOUVER, British Columbia , March 17, 2026 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a biotechnology company managing a portf ...

Summary of Zymeworks Conference Call Company Overview - **Company**: Zymeworks - **Key Product**: Zanidatamab, a bispecific HER2 antibody developed using the Azymetric platform, which allows for advanced antibody engineering and computational biology capabilities [2][3] Financial Position - **Current Cash Position**: $271 million in cash, plus a recent $250 million royalty note, totaling over $500 million available for strategic investments [10] - **Future Milestones**: Expected $440 million in royalties from zanidatamab upon regulatory approvals, with additional $90 million for a third indication [10][12] Pipeline and Development Strategy - **Pipeline Focus**: Zymeworks aims to develop assets to inflection points and then partner them out for upfront payments while retaining long-term royalties [4][5] - **Zanidatamab**: Positioned as a transformative HER2-targeted agent with multiple mechanisms of action, showing promising data in first-line GEA and breast cancer trials [14][15][16] - **Upcoming Approvals**: Anticipated approval for zanidatamab in the second half of the year in the U.S., with Jazz Pharmaceuticals committed to filings outside the U.S. [17] Clinical Data Highlights - **GEA Study**: Positive results in progression-free survival (PFS) and overall survival (OS) when combined with checkpoint inhibitor tislelizumab [15][16] - **Folate Receptor Alpha ADC**: Early clinical data shows a wide therapeutic index and a response rate in the early 60s%, with a focus on safety and efficacy [26][28] New Molecules and Partnerships - **Pasritamig**: A T-cell engager licensed to Johnson & Johnson, currently in pivotal studies, showing manageable safety and promising efficacy [35][37] - **ZW191 (Folate Receptor Alpha)**: First asset from the wholly owned pipeline, designed to be a potential best-in-class ADC with a focus on safety and efficacy [26][28] - **ZW209 (Tri-specific)**: Expected to enter clinical trials in 2026, designed for targeted T-cell activation to enhance immune response [38] Strategic Goals - **Partnership Strategy**: Zymeworks is actively seeking partnerships for its assets, focusing on long-term royalties and reducing financial liabilities [32][33] - **Future Milestones**: Key upcoming milestones include filing for zanidatamab approval, advancing pasritamig into phase 3 studies, and sharing data from the folate receptor alpha ADC [54][55] Conclusion - Zymeworks is positioned for significant growth with a robust pipeline and strategic partnerships, focusing on innovative therapies in oncology while maintaining a strong financial position to support its development goals [5][54]